{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:35:32Z","timestamp":1791380132003,"version":"4.3.3"},"reference-count":33,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Objective\nThis is the first multicenter, double blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of adjunctive zonisamide for the treatment of bipolar mania or mixed state.\nExperimental design\nOne hundred four patients with Bipolar Disorder, Type I, II or NOS, in a manic, hypomanic or mixed state of illness were randomized to either adjunctive zonisamide or placebo. The study consisted of three phases: a 7 to 30 day screening and stabilization phase, 6 weeks of blinded treatment and a 1 to 3 week discontinuation phase. The primary outcome variable for manic and hypomanic patients was the Young Mania Rating Scale (YMRS) both the YMRS and Montgomery Asberg Depression Rating Scale (MADRS) served as primary outcome variables for patients in mixed states. Secondary outcome measures included the Clinical Global Impression for Bipolar Disorder (CGI-BP), the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) and an a priori analysis of response and remission. Metabolic parameters including weight, waist-hip ratio, body mass index, fasting glucose, cholesterol and triglyceride levels were also analyzed. Side effects were measured using the SAFTEE.\nPrincipal observations\nThere were no statistically significant differences for any of the primary or secondary outcome measures between zonisamide and placebo-treated patients.\nConclusions\nIn contrast to previous studies that suggested efficacy of adjunctive zonisamide in bipolar mania or mixed state, these results were not confirmed in this double blind controlled study.<\/jats:p>","DOI":"10.64719\/pb.4068","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:02:23Z","timestamp":1761051743000},"page":"5-17","source":"Crossref","is-referenced-by-count":1,"title":["Zonisamide for Bipolar Disorder, Mania or Mixed States: A Randomized, Double Blind, Placebo-Controlled Adjunctive Trial"],"prefix":"10.64719","volume":"44","author":[{"given":"Deborah","family":"Dauphinais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Knable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Polanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry. 1994;51:8\u201319.","DOI":"10.1001\/archpsyc.1994.03950010008002"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disorders. 1998;50:143\u2013151.","DOI":"10.1016\/S0165-0327(98)00142-6"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME. Predictors of recurrence in bipolar disorder: Primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD) Am J Psychiatry. 2006;163:217\u2013224.","DOI":"10.1176\/appi.ajp.163.2.217"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Kanba S, Yagi G, Kamijima K, Suzuki T, Tajima O, Otaki J, Arata E, Koshikawa H, Nibuya M, Kinoshita N et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18(4):707\u2013715.","DOI":"10.1016\/0278-5846(94)90078-7"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Ghaemi SN, Shirzadi AA, Klugman J, Berv DA, Pardo TB, Filkowski MM. Is adjunctive open-label zonisamide effective for bipolar disorder? Journal of Affective Disorders. 2008;105:311\u2013314.","DOI":"10.1016\/j.jad.2007.05.011"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"McElroy SL, Suppes T, Keck PE, Black D, Frye MA, Altshuler LL, Nolen WA, Kupka RW, Leverich GS, Walden J, Grunze H, Post RM. Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. J Clin Psychiatry. 2005;66(5):617\u2013624.","DOI":"10.4088\/JCP.v66n0512"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Anand A, Bukhari L, Jennings SA, Lee C, Kamat M, Shekhar A, Nurnberger JI, Lightfoot J. A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. J Clin Psychiatry. 2005;66:195\u2013198.","DOI":"10.4088\/JCP.v66n0206"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Baldassano CF, Ghaemi NS, Chang A, Lyman A, Lipari M. Acute treatment of bipolar depression with adjunctive zonisamide: a retrospective chart review. Bipolar Disord. 2004;6(5):432\u2013434.","DOI":"10.1111\/j.1399-5618.2004.00143.x"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Ghaemi SN, Zablotsky B, Filkowski MM, Dunn RT, Pardo TB, Isenstein E, Baldassano CF. An open prospective study of zonisamide in acute bipolar depression. J Clin Psychopharmacol. 2006;26(4): 385\u2013388.","DOI":"10.1097\/01.jcp.0000227702.72117.f5"},{"key":"ref10","unstructured":"Oommen KJ, Mathews S. Zonisamide: a new antiepileptic drug. Clin Neuropharmacol. 1999;22(4):192\u2013200."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Ghaemi SN, Gaughan S. Novel anticonvulsants: a new generation of mood stabilizers? Harv Rev Psychiatry. 2000;8(1):1\u20137.","DOI":"10.3109\/hrp.8.1.1"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Elmslie JL, Silverstone JT, Mann JI, Williams SW, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry. 2000;61:179\u201384.","DOI":"10.4088\/JCP.v61n0306"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160(1):112\u2013117.","DOI":"10.1176\/appi.ajp.160.1.112"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry. 2003;64(12):1426\u20131435.","DOI":"10.4088\/JCP.v64n1205"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PE, Leverich GS, Altshuler L, Denicoff KD, Nolen WA, Kupka R, Grunze H, Walden J, Post RM. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63:207\u2013213.","DOI":"10.4088\/JCP.v63n0306"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Sills GJ, Brodie MJ. Pharmacokinetics and drug interactions with zonisamide. Epilepsia. 2007;48(3):435\u2013441.","DOI":"10.1111\/j.1528-1167.2007.00983.x"},{"key":"ref17","unstructured":"4th. Washington, DC: American Psychiatric Association Washington, APA Press; 1994. Diagnostic and Statistical Manual of Mental Disorders."},{"key":"ref18","unstructured":"Sheehan D, Janava J, Baker R, Harnett-Sheehan K, Knapp E, Sheehan M. Mini International Neuropsychiatric Interview. In: Sheehan D.V, Lecrubier Y, editors. Version 5.0.0. University of South Florida, Tampa and H\u00f4pital de la Salp\u00e9tri\u00e8re; Paris: 2006. Copyright 1992\u20132006."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry. 1978;133:429\u2013435.","DOI":"10.1192\/bjp.133.5.429"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u2013389.","DOI":"10.1192\/bjp.134.4.382"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Williams JBW, Kobak KA. Development and reliability of a structured interview guide for the Montgomery-Asberg Depression Rating Scale (SIGMA) Br J Psychiatry. 2008;192:52\u201358.","DOI":"10.1192\/bjp.bp.106.032532"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159\u2013171.","DOI":"10.1016\/S0165-1781(97)00123-6"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321\u2013326.","DOI":"10.1037\/t49981-000"},{"key":"ref24","unstructured":"Bray GA, Gray DS. Obesity Part I\u2014Pathogenesis. West J Med. 1988;149:429\u2013441."},{"key":"ref25","unstructured":"National Heart, Lung, and Blood Institute in cooperation with The National Institute of Diabetes and Digestive and Kidney Diseases. Rockville, MD: National Institutes of Health.; 1998. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. NIH Publication No. 98-4083."},{"key":"ref26","unstructured":"Rockville, MD: National Institute of Mental Health; 1986. Systematic Assessment for Treatment Emergent Effects (SAFTEE)"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet. 2001;357(9263):1191\u20131194.","DOI":"10.1016\/S0140-6736(00)04337-3"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Schulz KF, Altman DG, Moher D. for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Ann Int Med. 2010;152 Epub 24 March.","DOI":"10.1016\/j.ijsu.2010.09.006"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"McElroy SL, Kotwal R, Guerdjikova AI, Welge JA, Nelson EB, Lake KA, D\u2019Alessio DA, Keck, PE, Hudson JI. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry. 2006;67:1897\u20131906.","DOI":"10.4088\/JCP.v67n1209"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Gadde KM, Franciscy DM, Wagner HR, 2nd, Krishnan KRR. Zonisamide for weight loss in obese adults: A randomized controlled trial. JAMA. 2003;289(4):1820\u20131825.","DOI":"10.1001\/jama.289.14.1820"},{"key":"ref31","unstructured":"Orexigen Therapeutics, Inc. Orexigen Press Release. Available at http:\/\/ir.orexigen.com\/phoenix.zhtml?c=207034&p=irol-newsArticle. Accessed October 25, 2009 and October 12, 2010."},{"key":"ref32","unstructured":"Center Watch Weekly. 40. Vol. 13. Boston, MA: Center Watch; 2009. Endocrinology. Trials: Empatic 360; p. 14."},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Arias AJ, Feinn R, Oncken C, Covault J, Kranzler HR. Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J Clin Psychopharmacology. 2010;30(3):318\u2013322.","DOI":"10.1097\/JCP.0b013e3181db38bb"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:24:38Z","timestamp":1791314678000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/zonisamide-for-bipolar-disorder-mania-or-mixed-states-a-randomized-double-blind-placebo-controlled-adjunctive-trial\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4068","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}